Author:
Mitra Amitava,Wang Yaning
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference36 articles.
1. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, et al. Model-based drug development. Clin Pharmacol Ther. 2007;82(1):21–32.
2. Marshall S, Madabushi R, Manolis E, Krudys K, Staab A, Dykstra K, et al. Model-informed drug discovery and development: Current industry good practice and regulatory expectations and future perspectives. CPT Pharmacometrics Syst Pharmacol. 2019;8(2):87–96.
3. Zhu H, Huang SM, Madabushi R, Strauss DG, Wang Y, Zineh I. Model-informed drug development: A regulatory perspective on progress. Clin Pharmacol Ther. 2019;106(1):91–3.
4. Mullard A. $1.3 billion per drug? Nat Rev Drug Discov. 2020; 19(4) 226.
5. PDUFA reauthorization performance goals and procedural fiscal years 2018 through 2022. https://www.fda.gov/media/99140/download. Accessed 23 June 2022.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献